PD-L1
Device
Agilent Technologies, Inc.
Total Payments
$2.3M
Transactions
599
Doctors
68
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $483,988 | 87 | 0 |
| 2023 | $175,820 | 98 | 0 |
| 2020 | $584,118 | 233 | 4 |
| 2019 | $493,768 | 9 | 0 |
| 2018 | $473,744 | 94 | 41 |
| 2017 | $39,448 | 78 | 37 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 413 | 76.6% |
| Royalty or License | $464,161 | 13 | 20.6% |
| Travel and Lodging | $35,886 | 61 | 1.6% |
| Consulting Fee | $14,313 | 4 | 0.6% |
| Food and Beverage | $7,411 | 105 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,500 | 3 | 0.2% |
Payments by Type
Research
$1.7M
413 transactions
General
$527,270
186 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Identification of mechanisms of response and resistance to immunotherapy | Agilent Technologies, Inc. | $690,423 | 0 |
| A Phase II, open-label, multi-center trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel Cell Carcinoma | Ares Trading SA | $659,809 | 0 |
| A Phase II, open-label, multi-center trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel Cell Carcinoma | EMD Serono, Inc. | $373,385 | 0 |
Top Doctors Receiving Payments for PD-L1
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $2.2M | 426 |
| , MD | Anatomic Pathology | New Haven, CT | $7,028 | 2 |
| , M.D., PH.D | Hematology | Los Angeles, CA | $6,853 | 13 |
| , M.D | Anatomic Pathology | San Diego, CA | $6,296 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Chapel Hill, NC | $4,400 | 2 |
| , MD | Internal Medicine | Philadelphia, PA | $3,866 | 3 |
| , M.D | Student in an Organized Health Care Education/Training Program | Valhalla, NY | $2,584 | 2 |
| , M.D | Anatomic Pathology | Yorba Linda, CA | $2,572 | 13 |
| , M.D | Specialist | Seattle, WA | $2,062 | 4 |
| , MD | Anatomic Pathology & Clinical Pathology | Tinton Falls, NJ | $1,973 | 4 |
| , MD | Anatomic Pathology | Bronx, NY | $1,639 | 2 |
| , MD PHD | Neuropathology | Buffalo, NY | $1,500 | 1 |
| , MD | Immunopathology | Seattle, WA | $1,470 | 2 |
| , M.D | Clinical Pathology | Fort Myers, FL | $1,296 | 6 |
| , MD | Anatomic Pathology & Clinical Pathology | Los Angeles, CA | $1,087 | 4 |
| , M.D | Anatomic Pathology & Clinical Pathology | New Brunswick, NJ | $1,042 | 2 |
| , MD | Specialist | Seattle, WA | $1,000 | 4 |
| , M.D | Anatomic Pathology & Clinical Pathology | Hinsdale, IL | $962.72 | 5 |
| , M.D | Anatomic Pathology & Clinical Pathology | Aliso Viejo, CA | $940.32 | 4 |
| , M.D | Molecular Genetic Pathology | Chicago, IL | $876.28 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | Salt Lake City, UT | $876.28 | 2 |
| , M.D., M.S | Hematology | Los Angeles, CA | $843.51 | 3 |
| , M.D | Hematology | Tinley Park, IL | $809.60 | 2 |
| Farzaneh Sayedian | Anatomic Pathology | Morgantown, WV | $809.60 | 2 |
| , M.D | Anatomic Pathology & Clinical Pathology | Los Angeles, CA | $787.21 | 2 |
Ad
Manufacturing Companies
- Agilent Technologies, Inc. $1.2M
- Ares Trading SA $659,809
- EMD Serono, Inc. $373,385
Product Information
- Type Device
- Total Payments $2.3M
- Total Doctors 68
- Transactions 599
About PD-L1
PD-L1 is a device associated with $2.3M in payments to 68 healthcare providers, recorded across 599 transactions in the CMS Open Payments database. The primary manufacturer is Agilent Technologies, Inc..
Payment data is available from 2017 to 2024. In 2024, $483,988 was paid across 87 transactions to 0 doctors.
The most common payment nature for PD-L1 is "Unspecified" ($1.7M, 76.6% of total).
PD-L1 is associated with 3 research studies, including "Identification of mechanisms of response and resistance to immunotherapy" ($690,423).